ANI Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-04$94.48 RISE2026-03-13$70.49 PEAK2026-05-05$84.63 182d | -25.4% 129d | Missed | Missed | — | — | +20.1% 53d | Missed |
DROP2025-05-02$72.95 RISE2025-05-22$57.27 PEAK2025-08-19$90.12 109d | -21.5% 20d | Missed | Missed | — | — | +57.4% 89d | Missed |
DROP2024-08-30$63.75 RISE2024-12-20$53.35 PEAK2025-03-19$64.87 201d | -16.3% 112d | Missed | Missed | — | — | +21.6% 89d | Missed |
DROP2023-11-03$65.43 RISE2024-01-30$54.20 PEAK2024-03-27$69.69 145d | -17.2% 88d | Missed | Missed | — | — | +28.6% 57d | Missed |
DROP2023-11-03$65.43 RISE2023-12-06$48.72 PEAK2024-02-29$67.67 118d | -25.5% 33d | Missed | Missed | — | — | +38.9% 85d | Missed |
DROP2023-02-07$45.72 RISE2023-04-27$37.29 PEAK2023-07-03$54.02 146d | -18.4% 79d | Missed | Missed | — | — | +44.9% 67d | Missed |
DROP2023-02-07$45.72 RISE2023-03-24$37.61 PEAK2023-06-20$52.67 133d | -17.7% 45d | Missed | Missed | — | — | +40.0% 88d | Missed |
DROP2022-08-16$38.01 RISE2022-09-27$31.10 PEAK2022-11-30$41.95 106d | -18.2% 42d | Missed | Missed | — | — | +34.9% 64d | Missed |
DROP2022-02-15$40.25 RISE2022-06-16$23.09 PEAK2022-08-16$38.01 182d | -42.6% 121d | Missed | Missed | — | — | +64.6% 61d | Missed |
DROP2022-01-03$47.15 RISE2022-05-11$24.59 PEAK2022-08-08$34.87 217d | -47.8% 128d | Missed | Missed | — | — | +41.8% 89d | Missed |
DROP2021-12-23$50.90 RISE2022-03-16$26.91 PEAK2022-04-21$33.46 119d | -47.1% 83d | Missed | Missed | — | — | +24.3% 36d | Missed |
DROP2021-11-02$56.85 RISE2021-12-03$39.55 PEAK2021-12-23$50.90 51d | -30.4% 31d | Missed | Missed | — | — | +28.7% 20d | Missed |
DROP2021-05-07$38.60 RISE2021-08-19$26.48 PEAK2021-11-02$56.85 179d | -31.4% 104d | Missed | Missed | — | — | +114.7% 75d | Missed |
DROP2020-08-13$33.10 RISE2020-11-06$23.69 PEAK2021-01-19$32.34 159d | -28.4% 85d | Missed | Missed | — | — | +36.5% 74d | Missed |
DROP2020-06-08$34.88 RISE2020-09-24$26.86 PEAK2020-12-17$31.47 192d | -23.0% 108d | Missed | Missed | — | — | +17.2% 84d | Missed |
1–15 / 17 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ANI Pharmaceuticals (NASDAQ:ANIP) and the best and worst performers in the pharmaceuticals industry.
Last week's profit announcement from ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) was underwhelming for investors, despite...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Earlier in May 2026, ANI Pharmaceuticals reported first-quarter 2026 results showing higher sales and earnings versus a year ago, raised its full-year 2026 revenue and earnings guidance to about US$1.08 billion–US$1.14 billion, and authorized a new US$100 million share repurchase program funded from cash. The updated outlook underscores management’s confidence in the Rare Disease franchise, particularly Cortrophin Gel, which is expected to account for roughly 60% of 2026 revenue. With...
ANI Pharmaceuticals (NasdaqGM:ANIP) is sharpening its focus on specialty and rare disease products, including Cortrophin Gel and Iluvien. The company has updated its financial guidance and announced a new $100 million share repurchase program. Several top executives and directors have recently reported sizable insider sales of ANI Pharmaceuticals stock. ANI Pharmaceuticals trades at $78.01 per share, with the stock up 30.0% over the past year and 69.7% over three years. Over shorter...
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
Corporate Presentation 1 © 2026 ANI Pharmaceuticals, Inc. Presentation of financial information ...
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
ANI, Cummins and Seadrill have been highlighted in this Screen of The Week article.
ANI Pharmaceuticals, Inc. announces a share repurchase program. Under the program, the company will repurchase $100 million worth of its shares. The repurchases will be made using the Company's cash...
ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call May 8, 2026 8:00 AM EDTCompany ParticipantsIrina KofflerNikhil Lalwani - President, CEO &...
2026-05-08. The following slide deck was published by ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals (ANIP) beat Q1 revenue and EPS estimates, driven by 42% Cortrophin Gel growth. The company raised its full-year 2026 guidance, sending shares up 5.5% in pre-market trading.
ANI Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was USD 237.46 million compared to USD 197.12 million...
Presentation Operator MessageOperator Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. First Quarter 2026 Earnings Results Call. Please note, this call is being recorded.
BAUDETTE, Minn. — BAUDETTE, Minn. — ANI Pharmaceuticals Inc. on Friday reported first-quarter profit of $29.5 million. The Baudette, Minnesota-based company said it had net income of $1.28...
ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 analyst estimate. Raises FY2026 sales outlook from $1.055 billion-$1.115 billion to $1.080 billion-$1.140 billion
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.30 by 56.49 percent. This is a 20.59 percent increase over earnings of $1.70 per share from
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ANIP | -2.34% | +4.37% | -0.54% | +33.70% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -5.31% | +10.09% | +2.90% | +21.01% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 771.6K | $59.34M | 0.00% | Added+6.1% | 2026-03-31 |
| DEShaw | quant | 213.4K | $16.41M | 0.01% | Trimmed-15.8% | 2026-03-31 |
| RenTech | quant | 186.1K | $14.31M | 0.02% | Trimmed-40.8% | 2026-03-31 |
| TwoSigma | quant | 96.8K | $7.44M | 0.01% | Trimmed-46.6% | 2026-03-31 |
| FidelityFMR | fundamental | 18.8K | $1.44M | 0.00% | Added+90.5% | 2026-03-31 |
| Wellington | fundamental | 7.5K | $580.06K | 0.00% | Trimmed-4.5% | 2026-03-31 |
| TRowePrice | fundamental | 13.5K | $1.04K | 0.00% | Added+27.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-07upcoming | 2.00 | — | — |
| 2026-05-08 | 1.30 | 2.05 | +57.77% |
| 2026-02-27 | 1.98 | 2.33 | +17.85% |
| 2025-11-07 | 1.77 | 2.04 | +15.25% |
| 2025-08-08 | 1.42 | 1.80 | +26.77% |
| 2025-05-09 | 1.38 | 1.70 | +22.96% |
| 2025-02-28 | 1.44 | 1.63 | +13.59% |
| 2024-11-08 | 1.09 | 1.34 | +23.39% |
| 2024-08-06 | 0.95 | 1.02 | +7.37% |
| 2024-05-10 | 1.00 | 1.21 | +21.49% |
| 2024-02-29 | 0.86 | 1.00 | +16.96% |
| 2023-11-08 | 0.84 | 1.27 | +50.59% |
| 2023-08-09 | 0.67 | 1.28 | +92.00% |
| 2023-05-08 | 0.35 | 1.17 | +232.39% |
| 2023-03-09 | 0.67 | 0.76 | +13.10% |
| 2022-11-09 | 0.55 | 0.64 | +15.84% |